11 results
8-K
EX-99.2
XFOR
X4 Pharmaceuticals Inc
29 Nov 22
X4 Pharmaceuticals Announces Positive Top-Line Results from 4WHIM Global, Pivotal Phase 3 Trial of Once-Daily, Oral Mavorixafor in WHIM Syndrome
4:05pm
(50) 8 (47) Adults (≥18 years) n (%) 7 (50) 9 (53) Female Gender n (%) 9 (64) 9 (53) Previous Immunoglobulin Usage n (%) 6 (43) 8 (47) Screening ANC
PRE 14A
qqogd7yh
17 Apr 20
Preliminary proxy
5:13pm
8-K/A
EX-10.5
i8w4f4kkt90l htzvx
13 May 19
Financial Statements and Exhibits
4:58pm
8-K
EX-10.5
lfj4e
13 Mar 19
X4 Pharmaceuticals Completes Merger with Arsanis
5:28pm
- Prev
- 1
- Next